These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35781457)

  • 1. [Challenges in kidney disease: therapeutic potential of bardoxolone methyl].
    Yamawaki K
    Nihon Yakurigaku Zasshi; 2022; 157(4):261-264. PubMed ID: 35781457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bardoxolone ameliorates TGF-β1-associated renal fibrosis through Nrf2/Smad7 elevation.
    Song MK; Lee JH; Ryoo IG; Lee SH; Ku SK; Kwak MK
    Free Radic Biol Med; 2019 Jul; 138():33-42. PubMed ID: 31059771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bardoxolone methyl: drug development for diabetic kidney disease.
    Kanda H; Yamawaki K
    Clin Exp Nephrol; 2020 Oct; 24(10):857-864. PubMed ID: 32594372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model.
    Kaseda S; Sannomiya Y; Horizono J; Kuwazuru J; Suico MA; Ogi S; Sasaki R; Sunamoto H; Fukiya H; Nishiyama H; Kamura M; Niinou S; Koyama Y; Nara F; Shuto T; Onuma K; Kai H
    Kidney360; 2022 Apr; 3(4):687-699. PubMed ID: 35721612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nrf2 activator for the treatment of kidney diseases.
    Yamawaki K; Kanda H; Shimazaki R
    Toxicol Appl Pharmacol; 2018 Dec; 360():30-37. PubMed ID: 30248418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
    Nezu M; Suzuki N; Yamamoto M
    Am J Nephrol; 2017; 45(6):473-483. PubMed ID: 28502971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives.
    Tanase DM; Gosav EM; Anton MI; Floria M; Seritean Isac PN; Hurjui LL; Tarniceriu CC; Costea CF; Ciocoiu M; Rezus C
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keap1-Nrf2 signaling activation by Bardoxolone-methyl ameliorates high glucose-induced oxidative injury in human umbilical vein endothelial cells.
    Yang JL; Sun MY; Yuan Q; Tang S; Dong MJ; Zhang RD; Liu YY; Mao L
    Aging (Albany NY); 2020 Jun; 12(11):10370-10380. PubMed ID: 32484788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
    Lu MC; Ji JA; Jiang ZY; You QD
    Med Res Rev; 2016 Sep; 36(5):924-63. PubMed ID: 27192495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney.
    Reisman SA; Chertow GM; Hebbar S; Vaziri ND; Ward KW; Meyer CJ
    J Am Soc Nephrol; 2012 Oct; 23(10):1663-73. PubMed ID: 22859857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway.
    Wu J; Liu X; Fan J; Chen W; Wang J; Zeng Y; Feng X; Yu X; Yang X
    Toxicology; 2014 Apr; 318():22-31. PubMed ID: 24530882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease.
    Vaziri ND; Liu S; Farzaneh SH; Nazertehrani S; Khazaeli M; Zhao YY
    Free Radic Biol Med; 2015 Sep; 86():374-81. PubMed ID: 25930007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxico-pharmacological perspective of the Nrf2-Keap1 defense system against oxidative stress in kidney diseases.
    Saito H
    Biochem Pharmacol; 2013 Apr; 85(7):865-72. PubMed ID: 23333765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study.
    Ikejiri K; Suzuki T; Muto S; Takama H; Yamawaki K; Miyazawa T; Urakawa I; Aoki Y; Otsuki A; Katsuoka F; Kinoshita K; Nangaku M; Akizawa T; Yamamoto M
    Clin Exp Nephrol; 2024 Mar; 28(3):225-234. PubMed ID: 37962746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NRF2 in kidney physiology and disease.
    Bondi CD; Hartman HL; Tan RJ
    Physiol Rep; 2024 Mar; 12(5):e15961. PubMed ID: 38418382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bardoxolone: augmenting the Yin in chronic kidney disease.
    Thomas MC
    Diab Vasc Dis Res; 2011 Oct; 8(4):303-4. PubMed ID: 21933845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Directly interact with Keap1 and LPS is involved in the anti-inflammatory mechanisms of (-)-epicatechin-3-gallate in LPS-induced macrophages and endotoxemia.
    Chiou YS; Huang Q; Ho CT; Wang YJ; Pan MH
    Free Radic Biol Med; 2016 May; 94():1-16. PubMed ID: 26878775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease.
    Aminzadeh MA; Reisman SA; Vaziri ND; Shelkovnikov S; Farzaneh SH; Khazaeli M; Meyer CJ
    Redox Biol; 2013; 1(1):527-31. PubMed ID: 24363993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
    de Zeeuw D; Akizawa T; Audhya P; Bakris GL; Chin M; Christ-Schmidt H; Goldsberry A; Houser M; Krauth M; Lambers Heerspink HJ; McMurray JJ; Meyer CJ; Parving HH; Remuzzi G; Toto RD; Vaziri ND; Wanner C; Wittes J; Wrolstad D; Chertow GM;
    N Engl J Med; 2013 Dec; 369(26):2492-503. PubMed ID: 24206459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function.
    Nagasu H; Sogawa Y; Kidokoro K; Itano S; Yamamoto T; Satoh M; Sasaki T; Suzuki T; Yamamoto M; Wigley WC; Proksch JW; Meyer CJ; Kashihara N
    FASEB J; 2019 Nov; 33(11):12253-12263. PubMed ID: 31431054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.